AGMG 0201

Drug Profile

AGMG 0201

Alternative Names: AGMG0201

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnGes MG
  • Class Antihypertensives; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypertension

Most Recent Events

  • 08 Aug 2017 Preclinical trials in Hypertension in Japan (IV) before August 2017 (AnGes MG pipeline, August 2017)
  • 08 Aug 2017 AnGes MG plans a phase I trial for Hypertension in Australia (AnGes MG pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top